Cresco Labs is navigating a turbulent stretch of news flow after being named in a federal class action lawsuit accusing major cannabis operators of making misleading medical claims about marijuana products. The litigation surfaced just days before the company released first-quarter 2026 financial results and shortly before a separate announcement revealed that a previously awarded Texas medical cannabis license had been rescinded.
The developments place Cresco at the center of several of the cannabis industry’s biggest current themes: legal scrutiny over medical cannabis marketing, federal rescheduling, expansion into limited-license states, and ongoing uncertainty around regulatory frameworks.
Federal Lawsuit Targets Cresco and Other Major Cannabis Operators
The lawsuit, filed in federal court on May 4, names Cresco Labs, Green Thumb Industries, and Verano Holdings. Plaintiffs allege the companies made false or unsupported medical claims about cannabis products while failing to properly warn consumers about potential health risks.
Filed on behalf of 42 customers across multiple states, the suit argues the companies promoted cannabis as beneficial for a wide range of medical conditions despite what plaintiffs describe as insufficient scientific evidence supporting many of those claims.
The complaint seeks class certification for consumers who purchased cannabis products from the companies in recent years. Plaintiffs are pursuing restitution, disgorgement of profits, additional warning requirements, and restrictions on future medical marketing claims.
The litigation also alleges the companies participated in a broader effort through industry trade organizations to promote cannabis as medically effective while downplaying potential harms tied to mental and physical health.
The lawsuit references studies and medical analyses questioning the strength of evidence supporting cannabis use for many conditions. At the same time, it acknowledges that cannabis and cannabinoid-based treatments have demonstrated effectiveness for certain uses, including seizure disorders, chemotherapy-related nausea, appetite loss associated with AIDS, and muscle spasticity in multiple sclerosis.
The case arrives during a period when medical cannabis recognition is expanding at both state and federal levels.
Litigation Adds Pressure During Industry Push Toward Legitimacy
The timing of the lawsuit coincides with one of the strongest periods of federal reform momentum the cannabis industry has seen in years.
Cannabis operators have increasingly emphasized medical legitimacy and regulated consumer products as central pillars of their long-term growth strategies. Companies have invested heavily in branded retail, patient education, and regulated distribution networks as they attempt to position cannabis businesses closer to mainstream consumer packaged goods companies.
The new lawsuit directly challenges that positioning.
The complaint argues that cannabis operators overstated medical efficacy despite limited evidence for many conditions. Plaintiffs also allege that consumers paid inflated prices due to misleading representations about health and wellness benefits.
According to the Chicago Tribune, Verano responded by stating that similar lawsuits against cannabis MSOs had already faced setbacks in court earlier in the year. The company also argued that state medical cannabis programs, along with recent federal actions, recognize accepted medical uses for cannabis.
Cresco Labs declined to comment on the litigation.
The legal action also lands at a sensitive moment for the broader cannabis sector, which remains federally illegal despite legalization or medical access programs in dozens of states. That regulatory contradiction continues, leaving operators exposed to unusual legal and financial risks compared to traditional consumer industries.
Federal Rescheduling Continues to Shape Industry Outlook
Just three days after the lawsuit was reported, Cresco Labs released first-quarter 2026 earnings and highlighted recent federal cannabis reform developments as a major milestone for the industry.
The company pointed to the Trump Administration’s move to reclassify medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. Cresco described the development as the “most consequential reform” the industry has experienced to date.
Schedule III status could significantly change the financial profile of U.S. cannabis operators because it is expected to eliminate the impact of Internal Revenue Code Section 280E on qualifying medical cannabis operations. Under current rules, cannabis companies cannot deduct many standard business expenses because marijuana remains federally prohibited.
The issue has weighed heavily on profitability across the sector for years.
The contrast between federal recognition of medical cannabis and the allegations contained in the lawsuit has become one of the most striking aspects of the current situation surrounding the industry.
Cresco Reports Revenue Growth and Continued Market Expansion
Alongside the legal developments, Cresco reported first-quarter revenue of $151 million, gross profit of $75 million, and adjusted EBITDA of $33 million.
The company posted a net loss of $17 million for the quarter.
Cresco stated it maintained the number one market share position in multiple billion-dollar cannabis markets and continued expanding its operational footprint across several states.
The company also emphasized its continued focus on branded cannabis products, which remain a core part of Cresco’s broader business strategy.
As of March 31, 2026, Cresco reported:
- $67 million in cash, cash equivalents, and restricted cash
- $310 million in senior secured term loan obligations
- $19 million mortgage loan balance
The company’s financial update arrived during a period when cannabis operators are increasingly seeking to improve operational efficiency and preserve cash while awaiting broader federal reform measures to take effect.
Texas License Reversal Creates Another Unexpected Headline
Additional uncertainty emerged on May 11 when Cresco announced that a previously awarded Texas medical cannabis license had been rescinded following a revision to the state’s scoring methodology.
Earlier in May, the company disclosed that Cresco Labs Texas had been conditionally awarded a license under the Texas Compassionate Use Program (TCUP), a development widely viewed as strategically important because of Texas’ long-term market potential.
However, the Texas Department of Public Safety later announced that it had retroactively corrected the tabulation methodology used during the license selection process.
Under the revised calculations, Cresco’s conditional license was withdrawn and the company was moved to the program’s eligibility list instead.
Cresco stated it believes its application merits approval and said it is evaluating options to work with the state regarding the original determination.
The company added that it remains prepared to deploy operational and capital resources into Texas if permitted in the future.
Cannabis Sector Continues Operating in a Highly Reactive Environment
The sector remains heavily influenced by legal decisions, regulatory announcements, licensing outcomes, and evolving public policy discussions.
The lawsuit against Cresco and other MSOs could place additional attention on how cannabis companies market medical products, especially as federal agencies move closer toward broader normalization of cannabis regulation.
Cresco’s recent headlines encapsulate many of the conflicting forces currently shaping the cannabis industry:
- Growing federal recognition of medical cannabis
- Continuing legal disputes over medical claims
- Expanding state-level operations
- Persistent profitability challenges
- Ongoing licensing uncertainty
- Increasing scrutiny around industry marketing practices
The coming months are likely to determine whether the lawsuit develops into a legal challenge for the cannabis sector or remains a more isolated litigation campaign.
Meanwhile, federal cannabis reform discussions and upcoming rescheduling hearings continue serving as a major backdrop for the entire industry.
Rita Ferreira
Rita is a seasoned writer with over five years of experience, having worked with globally renowned platforms, including Forbes and Miister CBD. Her deep knowledge of hemp-related businesses and passion for delivering accurate and concise information distinguish her in the industry. Rita's contributions empower individuals and companies to navigate the complexities of the cannabis world, and her work remains a valuable resource for those seeking a deeper understanding of its potential.
